Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

TY - JOUR

T1 - Chronic kidney disease and arrhythmias

T2 - Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

AU - Turakhia, Mintu P.

AU - Blankestijn, Peter J.

AU - Carrero, Juan Jesus

AU - Clase, Catherine M.

AU - Deo, Rajat

AU - Herzog, Charles A.

AU - Kasner, Scott E.

AU - Passman, Rod S.

AU - Pecoits-Filho, Roberto

AU - Reinecke, Holger

AU - Shroff, Gautam R.

AU - Zareba, Wojciech

AU - Cheung, Michael

AU - Wheeler, David C.

AU - Winkelmayer, Wolfgang C.

AU - Wanner, Christoph

N1 - Funding Information: Conflict of interest: M.P.T. has received research support from AstraZeneca, Boehringer Ingelheim, Cardiva Medical, Janssen, Medtronic, and Veterans Health Administration; has served as a consultant to Akebia, AliveCor, Boehringer Ingelheim, Cardiva Medical, iBeat, iRhythm, Medtronic, Precision Health Economics, and St Jude Medical; has received speaker honoraria from Medscape/theheart.org; has reported equity in AliveCor, iBeat, Zipline Medical; and is an editor for JAMA Cardiology. P.J.B. has received research support from the Dutch Kidney Foundation, the European Commission, Medtronic, The Netherlands Organisation for Health Research and Development, and St. Jude Medical. All monies were paid to institution. J.J.C. has received institutional research grants from AstraZeneca, Vifor Fresenius Medical Care Renal Pharma and Swedish Heart and Lung Foundation and speaker honorarium from Vifor Fresenius Medical Care Renal Pharma. C.A.H. has served as a consultant to Abbvie, Bristol-Myers Squibb, Fibrogen, Relypsa, Sanifit, ZS Pharma; received research support from Amgen and Zoll; owns stock in Boston Scientific, GE, Johnson & Johnson and Merck. S.E.K. has received research support from WL Gore and Associates, Bayer and Bristol-Myers Squibb; and has served as a consultant to Abbvie, Boehringer Ingelheim and Johnson & Johnson. R.S.P. has received personal fees from Biotronic and Medtronic; non-financial support from Kardic; and research support from Pfizer. R.P.-F. has served on advisory boards and/or received speaker honoraria from Akebia, AstraZeneca, Baxter, Fresenius Medical Care, Janssen, and Novartis. He has also received research support from Baxter and Fresenius Medical Care. H.R. has received personal fees and non-financial support from Bristol-Myers Squibb and Pfizer. W.Z. has received research support from Boston Scientific and Zoll. D.C.W. has served as a consultant to Amgen, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, and Vifor Fresenius Medical Care Renal Pharma; and has received speaker honoraria from Amgen and Kyowa Kirin. W.C.W. has served as a scientific advisor to AMAG, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Vifor Fresenius Medical Care Renal Pharma, and ZS Pharma; has served on clinical trial executive committee for Akebia and endpoint adjudication committee for Medtronic; he has also served as a consultant to Relypsa and received speaker honorarium from Fibrogen. C.W. has served as a consultant to Boehringer-Ingelheim and Sanofi Genzyme. All other authors have nothing to disclose. Funding Information: The conference was sponsored by KDIGO (Kidney Disease: Improving Global Outcomes) and supported in part by unrestricted educational grants from AstraZeneca, Bayer HealthCare, Boston Scientific, Daiichi-Sankyo, Fresenius Medical Care, Sanofi-Genzyme, Medtronic, Relypsa, and Vifor Fresenius Medical Care Renal Pharma. All conference attendees received travel support for meeting participation.

PY - 2018/6/21

Y1 - 2018/6/21

UR - https://www.scopus.com/pages/publications/85049638583

U2 - 10.1093/eurheartj/ehy060

DO - 10.1093/eurheartj/ehy060

M3 - Review article

C2 - 29522134

SN - 0195-668X

VL - 39

SP - 2314-2325e

JO - European Heart Journal

JF - European Heart Journal

IS - 24

ER -